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Abstract
Background: Human immunodeficiency virus (HIV) infection is usually complicated by high rates of tuberculosis
(TB) co-infection. Impaired immune response has been reported during HIV/TB co-infection and may have
significant effect on anti-retroviral therapy (ART). TB/HIV co - infection is a major public health problem in Ethiopia.
Therefore, the aim of the study was to assess the effect of TB incidence on immunological response of HIV patients
during ART.
Methods: A retrospective follow-up study was conducted among adult HIV patients who started ART at the University
of Gondar Hospital. Changes in CD4+ T - lymphocyte count and incident TB episodes occurring during 42 months of
follow up on ART were assessed. Life table was used to estimate the cumulative immunologic failure. Kaplan-Meier
curve was used to compare survival curves between the different categories. Cox-proportional hazard model was
employed to examine predictors of immunological failure.
Results: Among 400 HIV patients, 89(22.2%) were found to have immunological failure with a rate of 8.5 per 100
person-years (PY) of follow-up. Incident TB developed in 26(6.5%) of patients, with an incidence rate of 2.2 cases per
100 PY. The immunological failure rate was high (20.1/100PY) at the first year of treatment. At multivariate analysis, Cox
regression analysis showed that baseline CD4+ T - cell count <100 cells/mm3 (adjusted hazard ratio (AHR) 1.8; 95%CI:
1.10 - 2.92, p = 0.023) and being male sex (AHR 1.6; 95%CI: 1.01 - 2.68, p = 0.046) were found to be significant predictors
of immunological failure. There was borderline significant association with incident TB (AHR 2.2; 95%CI: 0.94 - 5.09,
p = 0.06). The risk of immunological failure was significantly higher (38.5%) among those with incident TB compared
with TB - free (21.1%) (Log rank p = 0.036).
Conclusions: High incidence of immunological failure occurred within the first year of initiating ART. The proportions
of patients with impaired immune restoration were higher among patients with incident TB. Lower baseline CD4+
T - cells count of <100 cells/mm3 and being male sex were significant predictors of immunological failure. The result
highlighted the beneficial effects of earlier initiation of ART on CD4+ T - cell count recovery.
Keywords: Anti-retroviral therapy, Immunological failure, Incident TB
* Correspondence: abezew@gmail.com
1Department of Medical Microbiology, College of Medicine and Health
Sciences, School of Biomedical and Laboratory Sciences, University of
Gondar, Gondar, Ethiopia
Full list of author information is available at the end of the article
© 2014 Assefa et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
Assefa et al. BMC Infectious Diseases 2014, 14:468
http://www.biomedcentral.com/1471-2334/14/468
Background
Despite recent advances in anti-retroviral therapy (ART),
human immunodeficiency virus (HIV) infections and the
resulting acquired immunodeficiency syndrome (AIDS)
remain an important cause of morbidity and mortality
worldwide with 2.6 million new cases and 1.8 million
deaths by the year 2009 [1]. In Ethiopia, according to
the 2007 single point HIV prevalence estimate, there
were 1,216,908 adult people living with HIV (PLHIV), and
of these 397,818 expected to take ART treatment by the
year 2010 [2]. On the other hand, tuberculosis (TB) caused
by Mycobacterium tuberculosis, remains the leading causes
of death from infectious diseases worldwide. In 2012,
about 8.6 million incident TB and 1.3 million deaths due
to TB were reported globally. The majority of TB cases oc-
curred in Asian (58%) and African (27%) countries [3].
In developing countries, TB remains a major public
health threat among HIV-infected individuals [3,4]. HIV
is the most potent risk factor for TB and TB is the lead-
ing cause of morbidity and mortality in HIV/AIDS pa-
tients [5,6]. Tuberculosis enhances progression of HIV
infection and HIV increases the risk of infection as well
as reactivation of latent tuberculosis. It is estimated that
50 − 60% of PLHIV will develop TB disease in their life-
time in contrast with HIV negative persons, whose
lifetime risk is only 10% [4,7]. The proportion of TB cases
co-infected with HIV is highest in African countries. In
African countries, about 37% of TB cases were co-infected
with HIV which accounted for 75% of TB cases among
HIV positive people worldwide [3]. In 2007, based on
Federal HIV/AIDS Prevention and Control Office report in
Ethiopia, the TB/HIV co-infection rate was 20 - 50% [8].
According to WHO report, in 2012 the incidence of TB in-
fection in Ethiopia was 247 per 100,000 people and 10.2%
of them were estimated to have co-infection with HIV [3].
With the advent of ARV drugs, HIV/AIDS has become a
treatable chronic disease. Effective anti-retroviral therapy
(ARV) therapy is usually convoyed by an increase in the
number of CD4+ T - cells and the functional restoration of
patents’ immune response and decline in HIV viral load as
well. However, the requirement of regular and lifelong
medication of HIV patient is challenged with emergencies
of treatment failure [8-10]. Impaired immunological recov-
ery may indicate incomplete suppression of plasma HIV -
RNA which results ARV drug resistance [9]. HIV treatment
failure can be defined as progression of disease after ART
initiation. Anti-retroviral treatment failure can be assessed
clinically, immunologically and virologically. However, on
the basis of clinical criteria treatment failure can’t be con-
cluded. Despite viral load testing is preferred approach for
monitoring ART response, in resource limited settings, im-
munological failure criteria, trends in CD4+ T - cells counts
over time, remains the strongest predictor of treatment
failure [8].
The recovery of CD4+ T - cells count during ART in
HIV/TB co-infected patients is less clear. However, studies
assessing immune responses to ART have found poor
CD4+ T - cells recovery to occur in patients who develop
incident TB after initiating ART [11-16]. Moreover, in
spite of HIV statuses sever CD4+ T -lymphocytopenia has
been observed in TB patients [17]. An in vitro study indi-
cated that TB infection impairs cellular immune responses
through M. tuberculosis-induced apoptosis of T - cells
[18]. Therefore, TB may act as a cofactor that accelerates
the impairment of the immune function and shortens sur-
vival of HIV - infected individuals. Although TB/HIV co-
infection is a major public health problem in Ethiopia, no
studies have reported the effect of TB on immunological
responses of HIV patients during ART. Hence, assessing
the effect of TB on immunological responses of HIV pa-
tients will provide information for clinicians for appropriate
management of TB/HIV co-infected patients. Moreover,
policy makers and health professionals can use the findings
to design ART related programs. Therefore, the aim of this
study was to assess the effect of incident TB on immuno-
logical response of HIV/AIDS patients during ART at the
University of Gondar Hospital.
Methods
Study setting and population
The study was conducted at the University of Gondar
Hospital, North-west Ethiopia, in June 2013. University
of Gondar Hospital is a referral hospital with more than
400 beds serving a population of about 5 million people
in North-west Ethiopia. The hospital offers a wide range
of services including voluntary counseling and testing,
treatment, referral services, monitoring of treatment re-
sponse with CD4+ T - cells counts, follow-up and sup-
portive care of HIV-infected individuals. ART is provided
free of cost to all HIV - infected individuals in need of
treatment. The study populations were those patients who
are 15 years old and above and ever started ART at the
University of Gondar Hospital. Patients start ART based
on WHO criteria for the initiation of ART in adults and
adolescents; patients with CD4+ T - cell count <200 cell/
mm3 or WHO stage 4 irrespective of CD4+ T - cell count
or WHO stage 3 with CD4+ T - cell counts <350 cells/
mm3. Routine monitoring of CD4+ T - cell counts is per-
formed every six months, or more frequently if clinically
indicated [8]. All HIV patients were screened for TB at en-
rolment, and during each follow-up visit through clinical
evaluation and microbiological tests and chest-radiography
based on WHO national guidelines. Patients diagnosed
with incident TB were treated with a standard eight months
regimen with two months intensive phase, combination of
4 drugs (isoniazid, rifampicin, ethambutol and pyrazina-
mide), and a subsequent 6 months continuation phase, 2
drugs (isoniazid, ethambutol) [4]. Routine CD4+ T -
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lymphocyte count measurements were performed by FACS
count (Becton Dickinson) every 6 months or more fre-
quently if clinically indicated after initiating ART.
Study design and data collection
A retrospective follow-up study was conducted on pa-
tients initiating ART from the 1st of September 2007
and 30th of August 2008 at the University of Gondar
Hospital. This period was selected to collect patient’s in-
formation from sufficient follow-up time. Adult HIV pa-
tients whose charts were available and who had at least
6 months of follow - up (having at least two CD4+ T-cell
measurements) and started on first line ART during the
study period were eligible for the study. HIV/AIDS pa-
tients who had active TB (prevalent TB) at the initiation
of ART and missing charts or incomplete baseline and
follow-up data were excluded from the study. Changes
in CD4+ T - cells count and incident TB episodes occur-
ring during the 42 months of follow-up on ART were
assessed. Socio - demographic information of the pa-
tients and clinical characteristics such as time of ART
start, baseline and follow-up CD4+ T - cell count, and
WHO clinical stage, co-infection with TB, time of TB
development and functional status were extracted from
the hospital’s ART register. Baseline measurements of
CD4+ T - cell count was included if performed within
six months prior to ART initiation and once on treat-
ment follow-up measurements was included if per-
formed within ±2 months of the 6 month time points.
Data extraction format was prepared and pretested on
20 charts. The data were extracted from patients’ charts
by three nurses who had ART training and experience in
HIV care.
Definitions
Prevalent TB was defined as patients taking anti-TB
treatment at the time of starting ART. Incident TB was
defined as a new active TB developed after initiation of
ART. Immunological failure was defined based on WHO
criteria: decrease in CD4+ T - cell count to pre -ART
level or below, decrease in CD4+ T - cell count from
on-treatment peak value by more than 50% or persistent
CD4+ T - cell count <100 cells/mm3 after six months of
therapy [8]. Patients, who were died, transfer out or, lost -
to - follow-up or didn’t show the event until the last visit
was considered as censored.
Statistical methods
Immunologic failure rates were calculated per 100 per-
son years at risk. Data were entered and cleaned by
using Epi-Info version.3.5.3 then exported to Statistical
Package for the Social Sciences (SPSS) version 20. De-
scriptive analyses were used to determine baseline socio-
demographic and clinical characteristics of the patients.
Life table was used to estimate the cumulative probabil-
ities of immunologic failure. Kaplan-Meier survival
curve was used to estimate the median survival time
from initiation of ART to immunologic failure. Bivariate
and multivariate Cox-proportional hazard model was
employed to identify predictors of immunological failure.
Hazard Ratio (HR) with 95% confidence intervals were
computed and p-value < 0.05 was considered statistically
significant for all cases.
Ethical approval
The study was reviewed and approved by the Institu-
tional Review Board (IRB) of the University of Gondar.
Official permission was obtained from University of
Gondar Hospital management. The patient records
were anonymized and de-identified prior to analysis. In-
dividual records were coded and accessed only by re-
search staff.
Results
Baseline socio-demographic characteristics of patients
A total of 606 adult HIV/AIDS patients were newly en-
rolled to HIV care clinic from the 1st of September 2007
and 30th of August 2008 but 122 patients were excluded
due to missing charts or incomplete baseline and follow-
up data. Among 484 HIV patients who had at least 6
months of follow-up, 84(17.4%) had active TB at the ini-
tiation of ART and the analysis was restricted to those
who did not have active TB at ART start. Therefore, a
total of 400 adult HIV/AIDS patients record were ana-
lyzed. Of the 400 adult HIV/AIDS patients who met the
inclusion criteria for the study, 315 (78.8%) remained
within the programme at study censorship, 4 (1%) died,
67 (16.8%) transferred out and 14(3.5%) were lost to fol-
low - up from the programme. Of 400 adult HIV/AIDS
patients, the majority (64.5%) were females. The median
age of patients at ART start was 33 years (Inter Quartile
Range (IQR) = 27-40 years) and almost half of the pa-
tients were married (50.5%). One hundred seventeen
(29.3%) of the study participants had no formal education
and only 62 (15%) patients were employed (Table 1).
Baseline clinical characteristics of patients
During ART enrolment more than half (52%) of patients
were at WHO clinical stage III. At the time of ART initi-
ation, patients had advanced immunodeficiency with the
median baseline CD4+ T - cell counts of 152 cells/mm3
(IQR = 82 - 203 cells/mm3). One hundred and twenty
seven (31.8%) of patients had baseline CD4+ T - cell
counts <100 cells/mm3. Majority of the patients started
treatment with zidovudine (AZT)/lamivudine (3TC)/nevi-
rapine (NVP) or efavirenz (EFV) (47.3%) followed by teno-
fobir (TDF)/3TC/NVP or EFV (40.5%) and stavudine
(D4T)/3TC/NVP or EFV (12.3%) based combination first
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line ARV drug regimens. Three hundred and forty (85%)
patients were working by their functional status (Table 2).
Immunological failure after initiation of ART
Study participants were followed for a minimum of 6 and
a maximum of 42 months with total person-time follow-
up of 1042.7 person-years (PY). The median number of
CD4+ T - cell counts performed per patient during the
follow -up period was 7 (IQR = 6 - 8). Of the 400 HIV/
AIDS patients who had at least 6 months of follow -up, 85
(21.3%) patients were lost to follow - up before the study
censorship. Eighty nine (22.2%) of the patients were found
to have immunological failure. Based on WHO criteria, 49
(55%) immunological failure were defined by decrease in
CD4+ T - cell count to pre -ART level or below, 12
(13.5%) decrease in CD4+ T - cell count from on-treat-
ment peak value by more than 50% and 28 (31.5%) persist-
ent CD4+ T - cell count below 100 cells/mm3. The
median time for occurrence of immunological failure was
6 months (IQR = 6 - 12 months). The median time for im-
munological failure was 6 months for both TB and TB-
free cohorts. Among all 89 immunological failures, 60
(67.4%) patients were failed at 6 month of follow-up on
ART. The overall immunological failure rate of our cohort
was 30 per 100PY at the end of 6 months, 20.1 per 100 PY
at the end of one year, 16.2 per 100 PY at the end of 18
months, 13.0 per 100 PY at the end of two years, 11.1 per
100 PY at the end of 30 months, 10.8 per 100 PY at the end
of three years and 8.5 per 100 PY at the end of 42 months of
follow-up. The cumulative probability of survival of patients
from immunological failure at the end of 6 months was 85%
while at the end of one year was 79%, at the end of three
years 78% and at the end of 42 months 75% (Figure 1).
Active TB developed in 26(6.5%) patients within 42
months on ART, with an incidence rate of 2.2 cases per
100 PY of follow-up. The median time for development
of incident TB during the follow-up was 9.5 months
(IQR, 5.5 - 16.5 months). Among those who developed
TB during the follow-up time, 17(57.7%) of the incident
TB occurred within the first year of initiating ART. After
42 months on ART, the risk of immunologic failure was
38.5% versus 21.1% among patients with and without in-
cident TB respectively (log rank p = 0.036) (Figure 2).
Kaplan Meier survival analysis showed that the prob-
ability of survival of patients from immunological failure
was significantly lower among patients with baseline
CD4+ T - cell count <100 cells/mm3 when compared to
those CD4+ T - cell count of 100 cells/mm3 and above
(log rank test, p = 0.007) (Figure 3). In addition, male
patients showed lower immunological failure survival
than females (log rank p = 0.031) (Figure 4).
In multivariate Cox regression analysis baseline CD4+ T
- cell counts level <100 cells/mm3 (adjusted hazard ratio
(AHR) 1.7, 95%CI: 1.11 - 2.64, p = 0.015) and being male
sex (AHR 1.6, 95%CI: 1.01 - 2.37, p = 0.043) were found
to be significant predictors of immunological failure. Even
though the survival from immunological failure was sig-
nificantly lower among patients with incident TB (p =
0.036), Cox regression analysis showed borderline signifi-
cant association between incident TB and immunological
failure (HR 1.9, 95%CI: 0.97 - 3.7, p = 0.06) (Table 3).
Discussion
The baseline socio-demographic and immunological
characteristics of this cohort were similar to other ART
cohorts in sub-Saharan Africa, in which the majority of
patients started ART at an advanced stage of the diseases
and majority of the patients were females [6,10,12,19]. In
Table 1 Baseline socio-demographic characteristics of
HIV/AIDS patients who started ART from September 2007
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resource-limited settings evaluation of treatment out-
comes mainly relies on immunological findings. Effective
ARV therapy is usually convoyed by quantitative and func-
tional restoration of patents’ immune response. Immuno-
logical failure may indicate incomplete suppression of
plasma viral load [9]. In our study, 89 (22.2%) patients
were experienced immunological failure within 42 months
of follow-up. Of patients who have had immunological
failure, 60(67.4%) patients were failed at 6 month of follow
up. The immunological failure rate of our cohort was 8.5
per 100 patient-years. This finding is almost in line with
the report from Debremarkos, Ethiopia, in which the im-
munological failure rate was 8 per 100 PY [19]. However,
lower findings were reported from Latin America and Asia
with failure rate of 2.57 per 100 PY and 1.1per 100 PY of
follow - up respectively [20].
Table 2 Baseline clinical characteristics and TB incidence of HIV/AIDS patients who started ART from September 2007
to August 2008 at the University of Gondar Hospital
Variable Total Incident TB+ Incident TB-
Female sex (n[%]) 258(64.5) 18(69.2) 240(64.2)
Age (years, mean [SD]) 34.37 ± 9.29 35.4 ± 8.8 34.3 ± 9.3
WHO HIV clinical stage (n[%])
I 57(14.3) 2(3.5) 55(96.5)
II 86(21.5) 6(7.0) 80(93.0)
III 208(52.0) 13(6.2) 195(93.8)
IV 49(12.3) 5(10.2) 44(89.8)
CD4 count (cells/mm3, median [IQR]) 152(82, 203) 98(58,201.75) 153(86,203)
CD4 count (cell/mm3, n[%])
0-99 127(31.8) 13(10.4) 112(89.6)
≥100 170(42.5) 13(4.7) 262(95.3)
Initial ART Regimen (n[%])
d4T/3TC/NVP or EFV 49(12.3) 4(8.2) 45(91.8)
AZT/3TC/NVP or EFV 189(47.3) 15(7.9) 174(92.1)
TDF/3TC/NVP or EFV 162(40.5) 7(4.3) 155(95.7)
Functional status (n[%])
Working 340(85.0) 20(5.9) 320(94.1)
Ambulatory 49(12.3) 4(8.2) 45(91.8)
Bed ridden 11(2.8) 2(18.2) 9(81.8)
d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; AZT: zidovudine; EFV: efavirenz; TDF: tenofobir; TB: tuberculosis; HIV: human immunodeficiency virus; ART:
antiretroviral therapy; IQR: interquartile range; SD: standard deviation; WHO: world health organization.
Figure 1 Kaplan−Meier curve for immunological failure of HIV/
AIDS patients taking ART. The Kaplan-Meier curve indicated the
trends of cumulative survival of patients from immunological failure
within 42 months of follow up on ART.
Kaplan-Meier survival curves
Figure 2 Kaplan−Meier curve illustrating the probability of
immunological failure survival to development of incident TB.
The immunological failure survival was lower in patients with active
TB as compared to those patients remaining TB - free.
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In our cohort, the immunological failure rate showed
time-related downward trend with lowest failure rate oc-
curred at the end of the follow-up. The majority of im-
munological failure in our cohort was occurred at 6
months of ART enrolment (30 per 100 PY) which is
concordant with findings reported in other African
countries [6,19]. This might be due to the initiation of
ART at an advanced stage of HIV/AIDS diseases. Base-
line lower CD4+ T - cell counts associated with poor
CD4+ T - cell count restoration and maintain long term
lower immune response [10,19,21-23].
In this study, the log rank test showed that the immuno-
logical failure free survival proportion was significantly
lower among patients with incident TB when compared to
those patients remaining TB-free for the same follow-up
time on ART. However, in the multivariate Cox regression
analysis we observed borderline significant association
between incident TB and immunological failure. This
may be due to relatively small number of cases with in-
cident TB. Different studies reported that despite TB
treatment patients who developed TB after ART initi-
ation were more likely to have lower immune recovery.
Studies on South African [11] and Ugandan [12] co-
horts of HIV patients initiated on ART, incident TB
was associated with suboptimal CD4+ T - cell re-
sponses. Furthermore, a study from Senegal indicated
that independent of HIV status development of inci-
dent TB causes severe CD4+ T-lymphocytopenia [17].
These findings may suggest that incident TB during
ART is associated with long lasting immune suppres-
sion. Low baseline CD4+ T - cell counts at enrolment
to an ART programme is associated with increased
risks of TB and of mortality during the first year of
ART [6,7]. In this study the lower baseline CD4+ T -
cell counts may expose patients to an increased risk of
developing incident TB which can in turn contribute
to immunological failure. Another explanation for the
lower CD4+ T - cell recovery in patients with incident
TB during ART may be due to decreased adherence to
ART during TB treatment because of high pill burden
and side-effects [24].
The most important finding of our study was that in
multivariate Cox regression analysis lower baseline CD4+
T - cell counts were independently associated with im-
munological failure. This is supported by other studies
conducted in Debremarkos, Ethiopia [19] and Thailand
[21,22] in which immunological failures were significantly
associated with lower baseline CD4+ T - cell counts.
Moreover, this finding is concordant with other reports
where immune restoration is largely dependent on
baseline CD4+ T - cell count and thus the timing of
ART initiation is important in order to optimize the
CD4+ T - cell response to therapy [23]. These reports
may highlight that patients with low CD4+ T - cells
count at baseline have poor long term CD4+ T - cells
responses. Therefore, our finding supports the new
WHO 2013 recommendations of expanding eligibility
for ART initiation to CD4+ T - cell counts ≤500 cells/
mm3 for all adults and children above 5 years [25].
Although the causal relationship is not known, keep-
ing the report from Uganda [12] immunological failure
was also associated with male sex. Advanced baseline
WHO clinical stages and old age groups were signifi-
cant predictors of poor immunological responses dur-
ing ART [19]. However, in our study none of these factors
were found to be associated with non-immunological re-
sponses of patients on ART. Unidentified factors such as
opportunistic diseases and/or malnutrition might be the
prime determinants of the immune recovery in the
current study subjects.
Kaplan-Meier survival curves
Figure 3 Kaplan−Meier curve illustrating the probability of
survival from immunological failure based on baseline CD4+
T-cell count. The survival from immunological failure was lower in
patients with baseline CD4+ T - cell count of 0–99 cells/mm3 as
compared to those with CD4+ T - cell count of 100 cells/mm3
and above.
Kaplan-Meier survival curves
Figure 4 Kaplan−Meier curve illustrating the probability of
immunological failure survival to gender. The survival from
immunological failure was lower in male patients as compared to
those female patients.
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Study limitations
As a retrospective design our study had limitations. We
excluded a large number of patient charts that could not
be verified by chart review due to unavailability of full
information which may have introduced bias. Moreover,
because of the nature of the study design, it was difficult
to control all possible confounders like body mass index
and opportunistic infections other than TB. The sample
size was also too small to include representative incident
TB cases and with large sample size the effect of TB on
immunological failure could be more elaborated. Given
that virologic response is the preferred standard for
monitoring ART, this study only assessed immunological
responses of the patients and as a result that immuno-
logical failure could be related to viral resistance or non
adherence. Therefore, for better understanding of the as-
sociation between incident TB and CD4+ T - cell count
recovery of HIV patients during ART prospective cohort
study should be considered.
Conclusion
High immunological failure rate in our cohort was oc-
curred at six months of ART enrolment. The propor-
tions of patients with impaired immune restoration were
Table 3 Cox-proportional hazard analysis of factors associated with immunological failure among HIV/AIDS patients
who started ART from September 2007 to August 2008 at the University of Gondar Hospital
Variables Immunological failure Crude HR (95% CI) P Adjusted HR (95% CI) P
No Yes
no (%) no (%)
Gender
Female 102(71.8) 40(28.2) 1 1
Male 209(81) 49(19) 1.54(1.02-2.34) 0.042 1.6(1.01-2.68) 0.046
Age (in year)
16-30 130(78.8) 35(21.2) 1
31-50 164(77.7) 47(22.3) 1.06(.68-1.63) 0.812
> 50 17(70.8) 7(29.2) 1.37(.61-3.09) 0.443
Education
Primary and below 175(76.8) 53(23.2) 1.12(.75-1.74) 0.546
Secondary and above 136(79.1) 36(20.9) 1
WHO HIV clinical stage
I 47(82.5) 10(17.5) 1
II 65(75.6) 21(24.4) 1.44(.69-3.06) 0.344
III 161(77.4) 47(22.6) 1.31(.66-2.59) 0.438
IV 38(77.6) 11(22.4) 1.32(.56-3.12) 0.525
Baseline CD4+ count (cells/mm3)
0-99 87(69.6) 38(30.4) 1.72(1.13-2.62) 0.012 1.8(1.10-2.92) 0.023
≥100 224(81.5) 51(18.5) 1 1
Initial ART regimen
D4T/3TC/NVP or EFV 40(81.6) 9(18.4) 1
AZT/3TC/NVP or EFV 141(74.6) 48(25.4) 0.90(.43-1.89) 0.785
TDF/3TC/NVP or EFV 130(80.2) 32(19.8) 1.29(.83-2.02) 0.262
Functional status
Working 262(77.1) 78(22.9) 1
Ambulatory 39(79.6) 10(20.4) 1.44(.72-2.92) 0.301
Bed ridden 10(90.9) 1(9.1) 1.26(.58-2.75) 0.555
Incident TB
Yes 16(61.5) 10(38.5) 1.92(.99-3.72) 0.050 2.2(0.94-5.09) 0.063
No 295(78.9) 79(21.1) 1 1
d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; AZT: zidovudine; EFV: efavirenz; TDF: tenofobir; TB: tuberculosis; HIV: human immunodeficiency virus; ART:
antiretroviral therapy; IQR: inter-quartile range; SD: standard deviation; WHO: world health organization; HR: hazard ratio, P: p-value.
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significantly higher among patients who developed inci-
dent TB during ART. Lower baseline CD4+ T - cell
count of <100 cells/mm3 and being male sex were found
to be significant predictors of immunological failure.
The timing of initiation of ART was major determinants
of the change in CD4+ T - cells count recovery. The re-
sult highlighted the beneficial effects of earlier initiation
of ART on CD4+ T - cells recovery and strengthening
early detection of TB through active screening and ap-
propriate management of TB patients.
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